APA (7th ed.) Citation

Fatemah A. Alherz, Thanaa A. El-Masry, Ghaleb A. Oriquat, Engy Elekhnawy, Nora Hamad Al-Shaalan, Mohamed M. S. Gaballa, . . . Maysa M. F. El-Nagar. (2024). Hesperidin Nanoformulation: A Potential Strategy for Reducing Doxorubicin-Induced Renal Damage via the Sirt-1/HIF1-α/VEGF/NF-κB Signaling Cascade. MDPI AG.

Chicago Style (17th ed.) Citation

Fatemah A. Alherz, Thanaa A. El-Masry, Ghaleb A. Oriquat, Engy Elekhnawy, Nora Hamad Al-Shaalan, Mohamed M. S. Gaballa, Enas I. El Zahaby, and Maysa M. F. El-Nagar. Hesperidin Nanoformulation: A Potential Strategy for Reducing Doxorubicin-Induced Renal Damage via the Sirt-1/HIF1-α/VEGF/NF-κB Signaling Cascade. MDPI AG, 2024.

MLA (9th ed.) Citation

Fatemah A. Alherz, et al. Hesperidin Nanoformulation: A Potential Strategy for Reducing Doxorubicin-Induced Renal Damage via the Sirt-1/HIF1-α/VEGF/NF-κB Signaling Cascade. MDPI AG, 2024.